HTS fluorescence polarization assay for inhibitors of Keap1-Nrf2 interaction
View Patent ↗Disclosed are methods and kits for identifying modulators of the Keap1-Nrf2-ARE pathway. In particular, a high throughput fluorescent polarization assay is described that identifies small molecules that inhibit the binding of a fluorescently labeled Nrf2 peptide with the kelch domain of the Keap1 protein. Also provided are probes that can be used in the described fluorescent polarization assay. The small molecules identified using the described assay are useful for combating oxidative stress-related disorders, such as those associated with cancer, emphysema, Huntington's disease, light-induced retinal damage, and stroke.
1. A method for identifying an agent that inhibits a Keap1-Nrf2 interaction, the method comprising:
(a) providing a mixture comprising a Keap1-Kelch domain protein and a fluorescently labeled Nrf2 peptide that is capable of binding the Keap1-Kelch domain protein;
(b) adding a test agent to the mixture;
(c) determining the difference in the amount of fluorescently labeled Nrf2 peptide bound to the Keap1-Kelch domain protein in the presence and absence of the test agent; and
(d) identifying the test agent as an inhibitor of the Keap1-Nrf2 interaction if the amount of fluorescently labeled Nrf2 peptide bound to the Keap1-Kelch domain protein in the presence of the test agent is less than in the absence of the test agent; wherein the fluorescently labeled Nrf2 peptide has the sequence Leu-Asp-Glu-Glu-Thr-Gly-Glu-Phe-Leu-NH 2 (SEQ ID NO:12).
2. The method of claim 1 , wherein step (c) comprises:
(c1) determining the fluorescence polarization value;
(c2) determining the fraction of fluorescently labeled Nrf2 peptide bound to the Keap1-Kelch domain protein from the fluorescence polarization value; and
(c3) comparing the fraction of fluorescently labeled Nrf2 peptide bound to the Keap1-Kelch domain protein to the fraction of fluorescently labeled Nrf2 peptide bound to the Keap1-Kelch domain protein in the absence of the test compound.
3. The method of claim 2 , wherein step (c2) comprises converting the fluorescence polarization values to anisotropy values.
4. The method of claim 3 comprising calculating the Z′-factor from the anisotropy values.
5. The method of claim 4 , wherein a test agent is identified as an inhibitor if the Z′-factor is greater than 3.
6. The method of claim 1 further comprising performing the steps (a)-(c) a plurality of times, each time with a different concentration of the agent.
7. The method of claim 6 further comprising determining a K i value for the agent.
8. The method of claim 1 , wherein the fluorescently labeled Nrf2 peptide is labeled by a fluorophore selected from the group consisting of fluorescein isothiocyanate, BODIPY-FL, Cy3B and Cy5.